Xunming Biotech, a company focused on AI-driven antibody design, has secured $35 million in Series A+ funding. The round was led by Sequoia China with participation from MatrixPartners China and Boyuan Capital, alongside existing investors. Funds will be allocated to advancing their AuraIDE™ platform, enhancing foundation models and agent capabilities, and expanding their experimental facilities to streamline the drug discovery and development process. AI
IMPACT Accelerates AI integration in drug discovery, potentially speeding up the development of novel therapeutics.
RANK_REASON Significant funding round for an AI-focused biotech company.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →